Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLK-R044
- Development stage
- Preclinical
- Lead developer
- Shenzhen Yaoxin Biotechnology
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HLK-R044 is a preclinical-stage topical small molecule therapeutic candidate being developed by Shenzhen Yaoxin Biotechnology (also known as Pharmacin) for the treatment of nail psoriasis. The drug is specifically formulated for topical administration, designed to penetrate the nail plate and address the underlying inflammatory processes associated with psoriatic involvement of the nail bed and matrix. As of mid-2024, the specific molecular target and mechanism of action for HLK-R044 have not been publicly disclosed by the sponsor, although the company specializes in small molecule modulators for immunological and inflammatory diseases.
- Other names
- HLK-R044HLK-R-044HLK-R 044
Beyond the preview
Go deeper on HLK-R044.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLK-R044.